Sagimet Biosciences (SGMT) Insider Kemble Buys 39,567 Shares

Insider Buying and Selling at Sagimet Biosciences Inc.

On June 12, 2026, insider George Kemble along with peers Jennifer Jarrett and Anne Phillips each acquired 39,567 shares of Sagimet Biosciences Inc. (NasdaqGM: SGMT). These transactions add to the recent insider reports filed with the SEC, reflecting notable activity among key personnel at the biotechnology firm.

Stock Price Levels and Recent Trading

Sagimet Biosciences shares recently changed hands at $6.47 on Tuesday. Over the past year, the stock has moved between a low of $4.50 and a high of $11.45. The company's 50-day moving average sits at $9.33, while the 200-day moving average rests at $7.02. With a market capitalization of roughly $671.3 million, the healthcare firm continues to draw attention from market participants.

Insider Buying and Selling at Sagimet Biosciences Inc.

The recent filing details purchases executed on June 12, 2026. George Kemble picked up 39,567 shares. Jennifer Jarrett also added 39,567 shares on the same date, and Anne Phillips acquired an identical block of 39,567 shares. These transactions reflect multiple insiders building positions on the same day.

Analysts Set New Price Targets

Wall Street firms have remained active with updates and price targets for the stock. On October 5, 2026, HC Wainwright & Co. reiterated its buy rating with a $29.00 price target. Guggenheim maintained a buy rating with a $26.00 target on October 2, 2026, while Oppenheimer kept an outperform rating with a $38.00 target on October 1, 2026. On the same day, Citizens maintained its market outperform rating with a $27.00 target. Earlier in September, Barclays upgraded the stock to overweight with an 18.00 target, and Cantor Fitzgerald initiated coverage with an overweight rating and a 10.71 target. Overall, the stock carries a strong buy recommendation from analysts with a mean price target of $29.60 based on 10 opinions.

Inside the Pipeline at Sagimet Biosciences

Sagimet Biosciences is a clinical-stage biopharmaceutical firm based in San Mateo, California, focused on developing fatty acid synthase inhibitors. Its lead drug candidate, Denifanstat, targets metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. The company also advances other oncology and acne programs.

What to Watch at Sagimet Biosciences Inc.

Investors will look toward the company's next earnings report scheduled for November 12, 2026, for further updates on clinical trials and financial standing. As always, insider transactions provide a look at individual decisions but do not guarantee future stock movements.